Clinical Trials Browser

Phase 2 × demethoxycurcumin × 90 days × Clear all

NCT06063486 2026-03-27

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Phase 2 Recruiting

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis